Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Multicenter Phase II trial of MB-CART2019.1 for the Treatment of Patients with relapsed/refractory DLBCL

Proposed period of release:
01/01/2021 to 30/06/2022

Name of the Institute(s) or Company(ies)
Miltenyi Biotec GmbH, Friedrich-Ebert-Stra├če 68, Bergisch Gladbach, Germany;

3. Is the same GMO release planned elsewhere in the Community?
Austria; Belgium; Germany; Spain; France; Italy; Netherlands; Sweden; Lithuania;

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
Other: mammals

Identity of the GMO:
T cells transduced with a replication-deficient lentiviral vector harbouring the chimeric antigen receptor for targeting CD20 and CD19.

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known